Overview

This trial is active, not recruiting.

Condition chronic hepatitis b
Treatments nasvac, pegylated interferon alpha 2b
Phase phase 3
Sponsor Clinical Research Organization, Dhaka, Bangladesh
Start date June 2011
End date June 2013
Trial size 160 participants
Trial identifier NCT01374308, NASVAC01

Summary

The general objective of the present clinical trial is to compare the therapeutic efficacy of a combination therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) [later called NASVAC] with a commonly used antiviral drug, pegylated interferon in patients with chronic hepatitis B (CHB).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
nasvac
NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
(Active Comparator)
Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
pegylated interferon alpha 2b Pegasys
Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks

Primary Outcomes

Measure
Number of study participants with virological and or biochemical response as a measure of efficacy
time frame: At week 96

Eligibility Criteria

Male or female participants from 18 years up to 60 years old.

Inclusion Criteria: - HBsAg+ serology for more than 6 months before the beginning of the treatment. In the last six months, according to HBeAg serostatus, for: - HBeAg (-) patients, with a) baseline HBV DNA ≥ 103 and b) raised serum ALT (x >1 ULN) or significant hepatic necroinflammation and/or fibrosis (HAI-NI>4 and/or HAI-F >2) or liver stiffness >7.2 KPa. - HBeAg (+) patients, with a) baseline HBV DNA ≥ 104 and b) and raised serum ALT (x >1.5 ULN) or significant hepatic necroinflammation and or fibrosis (HAI-NI>4 and/or HAI-F >2) or liver stiffness >7.2 KPa. - Patients of both sex from 18 to 60 years-old - No specific hepatitis B treatment at least for 6 months previous to the inclusion - Voluntary signed informed consent to participate in the trial Exclusion Criteria: - Condition of HBV asymptomatic carrier or cirrhosis or patients with primary hepatocellular carcinoma - Positive serological markers for hepatitis C - Positive serological markers for HIV - Previous specific anti-hepatitis B treatment in the last 6 months. - Critically ill patient history of heart or renal failure, hypertension, hyperthyroidism, epilepsy, immunodeficiency diseases, malignancies or any non-controlled systemic disease. - Pregnancy or nursing women. Women in fertile age without any contraceptive methods. - Known severe allergic conditions (degree III or IV asthma, urticaria, dermatitis, bronchitis, etc. or hypersensitivity to any of the ingredients present in the preparation). - Severe psychiatric dysfunction or another limitation that prevents the patient's consent. - History of Autoimmune diseases (such as SLE, rheumatoid arthritis, multiple sclerosis, non controlled diabetes mellitus type 1) - History of other hepatic diseases of different etiology (such as alcoholism, autoimmune hepatitis, drug induced hepatitis, Wilson's diseases, hemochromatosis) - History of immune suppressive disorder or administration of immune suppressive-immune modulator drugs (including steroids) during or in the 6 months previous to the study. - Very high transaminase levels at the beginning of treatment (ALT over 500 U/L) suggesting a not stable disease with risk for patient's health or acute flares over 15 times the upper limit of normality.

Additional Information

Official title Phase IIII Study of a Therapeutic Vaccine Candidate Containing Hepatitis B Virus (HBV) Core Antigen (HBcAg) and HBV Surface Antigen (HBsAg) for Treatment of Patients With Chronic HBV Infection
Principal investigator Mamun A Mahtab, MSc MD FACG
Description To collect and assess data on the therapeutic potential of the NASVAC in CHB patients regarding: Reduction of the serum HBV DNA levels. Reduction in the levels of alanine aminotransferase (ALT) Clearance of hepatitis B e antigen (HBeAg) Negativation or lowering of HBsAg Anti-HBsAg/anti-HBeAg seroconversion An additional objective of this study is to reconfirm the safety of NASVAC in CHB patients that has previously been shown by us in Phase I-II clinical trial in CHB patients.
Trial information was received from ClinicalTrials.gov and was last updated in December 2012.
Information provided to ClinicalTrials.gov by Clinical Research Organization, Dhaka, Bangladesh.